跳转至内容
Merck
CN
  • Chronic hypoxia during development does not trigger pathologic remodeling of the chicken embryonic heart but reduces cardiomyocyte number.

Chronic hypoxia during development does not trigger pathologic remodeling of the chicken embryonic heart but reduces cardiomyocyte number.

American journal of physiology. Regulatory, integrative and comparative physiology (2015-10-02)
Hanna Österman, Isa Lindgren, Tom Lindström, Jordi Altimiras
摘要

Fetal growth restriction programs an increased risk of cardiovascular disease in adulthood, but the actual mechanisms of this developmental programming are not fully understood. Previous studies in mammalian models suggest that hearts of growth-restricted fetuses have reduced cardiomyocyte number due to reduced proliferation and premature cardiomyocyte maturation. Chicken embryos incubated under chronic hypoxia are also growth-restricted, have smaller hearts, and show signs of cardiac insufficiency posthatching. The aim of the present study was to investigate how chronic hypoxia (14% O2) during development affects cardiomyocyte mass and how myocardial structure is altered. Hypoxic incubation reproduced the well-characterized embryonic growth restriction and an increased ventricle-to-body mass ratio (at E11, E15, E17, and E19) with reduced absolute heart mass only at E19. Cell density, apoptosis, and cardiomyocyte size were insensitive to hypoxia at E15 and E19, and no signs of ventricular wall remodeling or myocardial fibrosis were detected. Bayesian modeling provided strong support for hypoxia affecting absolute mass and proliferation rates at E15, indicating that the growth impairment, at least partly, occurs earlier in development. Neither E15 nor E19 hearts contained binucleated cardiomyocytes, indicating that fetal hypoxia does not trigger early maturation of cardiomyocytes in the chicken, which contrasts with previous results from hypoxic rat pups. In conclusion, prenatal hypoxia in the chick embryo results in a reduction in the number of cardiomyocytes without inducing ventricular remodeling, cell hypertrophy, or premature cardiomyocyte maturation.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氢氧化钠, ACS reagent, ≥97.0%, pellets
Sigma-Aldrich
氢氧化钠, reagent grade, ≥98%, pellets (anhydrous)
Sigma-Aldrich
HEPES, ≥99.5% (titration)
Sigma-Aldrich
氢氧化钠 溶液, 50% in H2O
Sigma-Aldrich
HEPES, BioPerformance Certified, ≥99.5% (titration), suitable for cell culture
Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
氢氧化钠 溶液, BioUltra, Molecular Biology, 10 M in H2O
Sigma-Aldrich
氯化钠, Molecular Biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
氢氧化钠 溶液, 1.0 N, BioReagent, suitable for cell culture
Sigma-Aldrich
氯化钠 溶液, 5 M in H2O, BioReagent, Molecular Biology, suitable for cell culture
Sigma-Aldrich
氯化钠, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
氯化钠, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
氯化钠 溶液, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
氢氧化钠, BioXtra, ≥98% (acidimetric), pellets (anhydrous)
Sigma-Aldrich
氢氧化钠, puriss., meets analytical specification of Ph. Eur., BP, NF, E524, 98-100.5%, pellets
Sigma-Aldrich
L-谷氨酸, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
牛磺酸, ≥99%
Sigma-Aldrich
氢氧化钠, reagent grade, 97%, powder
Sigma-Aldrich
氢氧化钠, puriss. p.a., ACS reagent, reag. Ph. Eur., K ≤0.02%, ≥98%, pellets
Sigma-Aldrich
氢氧化钠, pellets, semiconductor grade, 99.99% trace metals basis
Sigma-Aldrich
氯化钠 溶液, 5 M
Sigma-Aldrich
L-谷氨酸, from non-animal source, meets EP testing specifications, suitable for cell culture, 98.5-100.5%
Sigma-Aldrich
氢氧化钠 溶液, 5.0 M
Sigma-Aldrich
HEPES缓冲溶液, 1 M in H2O
Sigma-Aldrich
氢氧化钠, beads, 16-60 mesh, reagent grade, 97%
Sigma-Aldrich
氢氧化钠, puriss. p.a., ACS reagent, K ≤0.02%, ≥98.0% (T), pellets
Sigma-Aldrich
牛磺酸, suitable for cell culture, meets USP testing specifications
Sigma-Aldrich
氯化钠, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
HEPES, BioUltra, Molecular Biology, ≥99.5% (T)
Sigma-Aldrich
氢氧化钠, reagent grade, 97%, flakes